RU98102116A - (1S, 2S) -1- (4-HYDROXYPHENYL) -2- (4-HYDROXY-4-Phenylpiperidin-1-IL) -1-PROPANO LMETANSULPHONATE TRIHYDRATE - Google Patents

(1S, 2S) -1- (4-HYDROXYPHENYL) -2- (4-HYDROXY-4-Phenylpiperidin-1-IL) -1-PROPANO LMETANSULPHONATE TRIHYDRATE

Info

Publication number
RU98102116A
RU98102116A RU98102116/04A RU98102116A RU98102116A RU 98102116 A RU98102116 A RU 98102116A RU 98102116/04 A RU98102116/04 A RU 98102116/04A RU 98102116 A RU98102116 A RU 98102116A RU 98102116 A RU98102116 A RU 98102116A
Authority
RU
Russia
Prior art keywords
disease
dopamine
agonists
mammal
effective amount
Prior art date
Application number
RU98102116/04A
Other languages
Russian (ru)
Other versions
RU2140910C1 (en
Inventor
М.Андино Марта
Г.Синэй Терри
Ф.Физ Юджин
Original Assignee
Пфайзер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Инк. filed Critical Пфайзер Инк.
Priority claimed from PCT/IB1996/000592 external-priority patent/WO1997007098A1/en
Application granted granted Critical
Publication of RU98102116A publication Critical patent/RU98102116A/en
Publication of RU2140910C1 publication Critical patent/RU2140910C1/en

Links

Claims (12)

1. Тригидрат метансульфоната (1S,2S)-1-(4-гидроксифенил)-2-(4-гидрокси-4-фенилпиперидин-1-ил)-1-пропанола.1. Methanesulfonate trihydrate (1S, 2S) -1- (4-hydroxyphenyl) -2- (4-hydroxy-4-phenylpiperidin-1-yl) -1-propanol. 2. Фармацевтическая композиция для лечения заболевания, выбранного из группы, включающей дегенеративные заболевания ЦНС, такие как припадок, болезнь Альцгеймера, болезнь Паркинсона и болезнь Хантингтона, эпилепсию, состояние страха, церебральную ишемию, мышечные спазмы, слабоумие, вызванное множественными инфарктами, травматическое поражение головного мозга, боль, слабоумие, вызванное СПИДом, гипогликемию, мигрень, боковой амиотрофический склероз, зависимость от лекарств и алкоголя, синдромы отмены лекарств и алкоголя, психотические состояния и недержание мочи у млекопитающих, в том числе у человека, содержащая тригидрат мезилатной соли по п.1 в эффективном количестве, и фармацевтически приемлемый носитель. 2. A pharmaceutical composition for treating a disease selected from the group consisting of degenerative diseases of the central nervous system, such as a seizure, Alzheimer's disease, Parkinson's disease and Huntington's disease, epilepsy, a state of fear, cerebral ischemia, muscle cramps, dementia caused by multiple heart attacks, traumatic head injury brain, pain, dementia caused by AIDS, hypoglycemia, migraine, amyotrophic lateral sclerosis, drug and alcohol addiction, drug and alcohol withdrawal syndromes, psychotic standing and urinary incontinence in a mammal, including a human, comprising the trihydrate mesylate salt according to claim 1 in an effective amount and a pharmaceutically acceptable carrier. 3. Фармацевтическая композиция по п.2, отличающаяся тем, что эффективным количеством является количество, эффективное для антагонистического взаимодействия с NMDA рецепторами. 3. The pharmaceutical composition according to claim 2, characterized in that the effective amount is an amount effective for antagonistic interaction with NMDA receptors. 4. Фармацевтическая композиция по п.2, отличающаяся тем, что эффективным количеством является количество, эффективное для лечения каждого заболевания. 4. The pharmaceutical composition according to claim 2, characterized in that the effective amount is an amount effective to treat each disease. 5. Способ лечения заболевания, выбранного из группы, включающей дегенеративные заболевания ЦНС, такие как припадок, болезнь Альцгеймера, болезнь Паркинсона и болезнь Хантингтона, эпилепсию, состояние страха, церебральную ишемию, мышечные спазмы, слабоумие, вызванное множественными инфарктами, травматическое поражение головного мозга, боль, слабоумие, вызванное СПИДом, гипогликемию, мигрень, боковой амиотрофический склероз, зависимость от лекарств и алкоголя, синдромы отмены лекарств и алкоголя, психотические состояния и недержание мочи у млекопитающих, в том числе у человека, заключающийся во введении млекопитающему тригидрата мезилатной соли по п.1 в эффективном количестве. 5. A method of treating a disease selected from the group comprising degenerative diseases of the central nervous system, such as a seizure, Alzheimer's disease, Parkinson's disease and Huntington's disease, epilepsy, a state of fear, cerebral ischemia, muscle cramps, dementia caused by multiple heart attacks, traumatic brain damage, pain, AIDS-related dementia, hypoglycemia, migraine, amyotrophic lateral sclerosis, drug and alcohol addiction, drug and alcohol withdrawal syndromes, psychotic conditions and urinary incontinence in mammals, including humans, comprising administering to the mammal a mesylate salt trihydrate according to claim 1 in an effective amount. 6. Способ по п.5, отличающийся тем, что эффективным количеством является количество, оказывающее антагонистическое действие на NMDA рецепторы. 6. The method according to claim 5, characterized in that the effective amount is the amount that has an antagonistic effect on NMDA receptors. 7. Способ по п.5, отличающийся тем, что эффективным количеством является количество, эффективное для лечения каждого заболевания. 7. The method according to claim 5, characterized in that the effective amount is an amount effective to treat each disease. 8. Способ лечения болезни Паркинсона у млекопитающего, включающий введение указанному млекопитающему эффективного для лечения болезни Паркинсона количества синергического сочетания тригидрата мезилатной соли по п.1 (1S, 2S)-1-(4-гидроксифенил)-2-(4-гидрокси-4-фенил-пиперидин-1-ил)-1-пропанола и средства, способного восстанавливать баланс возбудительной обратной связи из вентрального латерального ядра таламуса в кору головного мозга. 8. A method of treating Parkinson’s disease in a mammal, comprising administering to said mammal a quantity of synergistic combination of mesylate salt trihydrate effective for treating Parkinson’s disease according to claim 1 (1S, 2S) -1- (4-hydroxyphenyl) -2- (4-hydroxy-4 -phenyl-piperidin-1-yl) -1-propanol and an agent capable of restoring the balance of excitatory feedback from the ventral lateral nucleus of the thalamus to the cerebral cortex. 9. Способ лечения болезни Паркинсона у млекопитающего, включающий лечение указанного млекопитающего эффективным для лечения болезни Паркинсона количеством синергического сочетания тригидрата мезилатной соли по п.1 и средства, повышающего возбудительную обратную связь, которое выбрано из группы, включающей агонисты допамина, агонисты допамина D1, агонисты допамина D2, агонисты взаимодействия допамин\ адренорецептор, агонисты взаимодействия допамин\ 5-НТ ингибитор поглощения\5-НТ-1А, агонисты взаимодействия допамин\ опиат, агонисты адренорецепторов, агонисты взаимодействия a2-адренорецептор\ допамин D2, ингибиторы поглощения допамина, ингибиторы моноаминоксидазы, ингибиторы моноаминоксидазы-В, ингибиторы СОМТ, ингибиторы трансфераз и леводопы. 9. A method of treating Parkinson’s disease in a mammal, comprising treating said mammal with an effective amount of a synergistic combination of mesylate salt trihydrate for treating Parkinson’s disease according to claim 1 and an excitatory feedback enhancer selected from the group consisting of dopamine agonists, dopamine D1 agonists, agonists dopamine D2, dopamine \ adrenoreceptor interaction agonists, dopamine \ 5-HT interaction agonists, 5-HT-1A absorption inhibitor, dopamine \ opiate interaction agonists, adrenor agonists receptors, a2-adrenoreceptor \ dopamine D2 interaction agonists, dopamine uptake inhibitors, monoamine oxidase inhibitors, monoamine oxidase-B inhibitors, COMT inhibitors, transferase and levodopa inhibitors. 10. Способ по п. 9, где указанный реагент, повышающий возбудительную обратную связь, представляет собой леводопу. 10. The method according to p. 9, where the specified reagent that increases the excitatory feedback, is a levodopa. 11. Способ по любому из пп.5-7, где заболевание, которое подлежит лечению, представляет собой болезнь Паркинсона. 11. The method according to any one of claims 5-7, wherein the disease to be treated is Parkinson's disease. 12. Способ по любому из пп.5-7, где заболевание, которое подлежит лечению, представляет собой травматическое поражение головного мозга или церебральную ишемию. 12. The method according to any one of claims 5 to 7, wherein the disease to be treated is a traumatic brain lesion or cerebral ischemia.
RU98102116A 1995-08-11 1996-06-20 (1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidine-1-yl)-1-propanol methanesulfonate trihydrate RU2140910C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US223895P 1995-08-11 1995-08-11
US60/002,238 1995-08-11
PCT/IB1996/000592 WO1997007098A1 (en) 1995-08-11 1996-06-20 (1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanolmethanesulfonate trihydrate

Publications (2)

Publication Number Publication Date
RU98102116A true RU98102116A (en) 1999-11-10
RU2140910C1 RU2140910C1 (en) 1999-11-10

Family

ID=21699847

Family Applications (1)

Application Number Title Priority Date Filing Date
RU98102116A RU2140910C1 (en) 1995-08-11 1996-06-20 (1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidine-1-yl)-1-propanol methanesulfonate trihydrate

Country Status (41)

Country Link
US (1) US6008233A (en)
EP (1) EP0843661B1 (en)
JP (1) JP3099072B2 (en)
KR (1) KR100291882B1 (en)
CN (2) CN1198739A (en)
AP (1) AP755A (en)
AR (1) AR004676A1 (en)
AT (1) ATE215072T1 (en)
AU (1) AU710984B2 (en)
BG (1) BG63678B1 (en)
BR (1) BR9610766A (en)
CA (1) CA2228752C (en)
CO (1) CO4750830A1 (en)
CZ (1) CZ296236B6 (en)
DE (1) DE69620191T2 (en)
DK (1) DK0843661T3 (en)
DZ (1) DZ2083A1 (en)
ES (1) ES2170857T3 (en)
GT (1) GT199600051A (en)
HR (1) HRP960372B1 (en)
HU (1) HUP9802862A3 (en)
IL (1) IL122649A (en)
IS (1) IS1945B (en)
MA (1) MA23957A1 (en)
NO (1) NO310458B1 (en)
NZ (1) NZ309134A (en)
OA (1) OA10664A (en)
PE (1) PE4898A1 (en)
PL (1) PL185603B1 (en)
PT (1) PT843661E (en)
RO (1) RO120134B1 (en)
RS (1) RS49521B (en)
RU (1) RU2140910C1 (en)
SA (1) SA96170171B1 (en)
SK (1) SK284209B6 (en)
TN (1) TNSN96104A1 (en)
TR (1) TR199800208T1 (en)
TW (1) TW495502B (en)
UA (1) UA59341C2 (en)
WO (1) WO1997007098A1 (en)
ZA (1) ZA966760B (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2197451C (en) * 1994-08-18 2001-01-23 Bertrand L. Chenard Neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and 1-(4-hydrophenyl)-2-(piperidinyl-1)-alkanol derivatives
RU2140910C1 (en) * 1995-08-11 1999-11-10 Пфайзер Инк. (1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidine-1-yl)-1-propanol methanesulfonate trihydrate
GB9820405D0 (en) 1998-09-18 1998-11-11 Smithkline Beecham Plc Process
WO2000061558A1 (en) * 1999-04-09 2000-10-19 Mochida Pharmaceutical Co., Ltd. Remedies for neuropathic pain
GB9920919D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel compound
GB9920917D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel process
US6620830B2 (en) * 2000-04-21 2003-09-16 Pfizer, Inc. Thyroid receptor ligands
YU27701A (en) * 2000-04-28 2003-04-30 Pfizer Products Inc. Process for the preparation of the mesylate salt trihydrate of 1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl) -1-propanol
YU27801A (en) * 2000-04-28 2003-04-30 Pfizer Products Inc. Process for the preparations of the mesylate salt trihydrate of 1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl) -1-propanol and intermediates useful therefor
AU2001283393B2 (en) * 2000-08-16 2005-09-22 Pharmacia & Upjohn Company Compounds for the treatment of addictive disorders
EP1186303A3 (en) * 2000-09-06 2003-12-10 Pfizer Products Inc. Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
EP1674087A1 (en) 2000-10-02 2006-06-28 Pfizer Products Inc. Prophylactic use of n-methyl-d-aspartate (NMDA) antagonists
IL145584A0 (en) * 2000-10-02 2002-06-30 Pfizer Prod Inc Nmda nr2b antagonists for treatment
UA73619C2 (en) * 2000-12-13 2005-08-15 Pfizer Prod Inc Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
IL161308A0 (en) 2001-10-19 2004-09-27 Toyama Chemical Co Ltd Alkyl ether derivatives or their salts
KR100517638B1 (en) 2002-04-08 2005-09-28 주식회사 엘지생명과학 New process for preparing acid salts of Gemifloxacin
CN103936690B (en) 2005-10-25 2016-06-08 盐野义制药株式会社 Aminodihydrothiazinederivative derivative
MX2009011498A (en) 2007-04-24 2009-11-10 Shionogi & Co Aminodihydrothiazine derivatives substituted with cyclic groups.
EP2151435A4 (en) 2007-04-24 2011-09-14 Shionogi & Co Pharmaceutical composition for treatment of alzheimer's disease
KR20130018370A (en) 2008-06-13 2013-02-20 시오노기세야쿠 가부시키가이샤 SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING β-SECRETASE-INHIBITING ACTIVITY
JPWO2010047372A1 (en) 2008-10-22 2012-03-22 塩野義製薬株式会社 2-Aminopyrimidin-4-one and 2-aminopyridine derivatives having BACE1 inhibitory activity
WO2011071135A1 (en) 2009-12-11 2011-06-16 塩野義製薬株式会社 Oxazine derivative
US8927721B2 (en) 2010-10-29 2015-01-06 Shionogi & Co., Ltd. Naphthyridine derivative
EP2634188A4 (en) 2010-10-29 2014-05-07 Shionogi & Co Fused aminodihydropyrimidine derivative
WO2012147763A1 (en) 2011-04-26 2012-11-01 塩野義製薬株式会社 Oxazine derivative and bace 1 inhibitor containing same
WO2014065434A1 (en) 2012-10-24 2014-05-01 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity
WO2016044323A1 (en) 2014-09-15 2016-03-24 Rugen Holdings (Cayman) Limited Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists
EP3197440A4 (en) * 2014-09-22 2018-04-18 Rugen Holdings (Cayman) Limited Treatment of anxiety disorders and autism spectrum disorders
WO2016126869A1 (en) 2015-02-04 2016-08-11 Rugen Holdings (Cayman) Limited 3,3-difluoro-piperidine derivatives as nr2b nmda receptor antagonists
JP6876625B2 (en) 2015-06-01 2021-05-26 リューゲン ホールディングス （ケイマン） リミテッド 3,3-Difluoropiperidine carbamate heterocyclic compound as NR2BNMDA receptor antagonist
US11000526B2 (en) 2016-11-22 2021-05-11 Rugen Holdings (Cayman) Limited Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272160A (en) * 1989-05-17 1993-12-21 Pfizer Inc 2-piperidino-1-alkanol derivatives as antiischemic agents
WO1990014087A1 (en) * 1989-05-17 1990-11-29 Pfizer Inc. 2-piperidino-1-alkanol derivatives as antiischemic agents
CA2197451C (en) * 1994-08-18 2001-01-23 Bertrand L. Chenard Neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and 1-(4-hydrophenyl)-2-(piperidinyl-1)-alkanol derivatives
RU2140910C1 (en) * 1995-08-11 1999-11-10 Пфайзер Инк. (1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidine-1-yl)-1-propanol methanesulfonate trihydrate

Similar Documents

Publication Publication Date Title
RU98102116A (en) (1S, 2S) -1- (4-HYDROXYPHENYL) -2- (4-HYDROXY-4-Phenylpiperidin-1-IL) -1-PROPANO LMETANSULPHONATE TRIHYDRATE
Wei et al. Dantrolene is cytoprotective in two models of neuronal cell death
US7105504B2 (en) Combination of a CB1 receptor antagonist and of a product which activates dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease
RU96109832A (en) SYNERGISTIC TREATMENT OF PARKINSONISM
BR9602485A (en) Method for the treatment of Parkinson's disease pharmaceutical composition first pharmaceutical composition and method for obtaining antiParkinson effect
EP2942082A3 (en) A2A receptor antogonists for use in the treatment of movement disorders
JP2009007366A (en) Use of 2-amino-4-(4-fluorobenzylamino)-1-ethoxycarbonylaminobenzene for treatment of neurodegenerative disorders
CA2246839A1 (en) Pharmaceutical compositions containing ampa receptor antagonists for treating dyskineslas associated with dopamine agonist therapy
WO1998008546A3 (en) Therapeutic combinations of rar antagonists and rxr agonists and use thereof
Pellejero et al. Effects of methoxamine and a-adrenoceptor antagonists, prazosin and yohimbine, on the sleep-wake cycle of the rat
RU2006138495A (en) USE OF RECEPTOR AGONISTS ACTIVATED BY DELTA PEROXISOMIS PROLIFERATOR FOR TREATMENT OF PC AND OTHER DEMIELINIZING DISEASES
CN106456637B (en) Pharmaceutical use of (S) -pirlindole and pharmaceutically acceptable salts thereof
RU2336077C2 (en) Alpha-aminoamide derivatives used as antimigraine agents
Zipp et al. Lamotrigine-antiparkinsonian activity by blockade of glutamate release?
KR102232198B1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
KR910000151A (en) How to Treat Cerebral Anemia
DE69721005D1 (en) USE OF GALANINE TO REPAIR NERVOUS DAMAGE
KR20000075895A (en) The use of levobupivacaine or ropivacaine in treating migraine
DE69814089T2 (en) USE OF A DRAFLAZINE ANALOGUE FOR TREATMENT
RU96117381A (en) NEUROPROTECTIVE COMPOUNDS
Pizzanelli et al. Lack of α1b‐adrenergic receptor protects against epileptic seizures
CA2246560A1 (en) Methods of administering an ampa receptor antagonist to treat dyskinesias associated with dopamine agonist therapy
Craig et al. Cobalt-induced focal seizures: neuronal networks and actions of antiepileptic drugs
KR960040360A (en) Synergistic treatment of Parkinson's disease
Jaw et al. Effects of glutamate receptor antagonists on posthypxic myoclonus in rats